Categories Earnings, Health Care

Amarin Corp tops the market in Q1 on Vascepa strength

Amarin Corporation (NASDAQ: AMRN) on Wednesday said its revenues soared 67% to $73.3 million, riding on the strong demand for its Vascepa capsules as well as higher commercialization fees from its licensed partners. The top line surpassed Wall Street projection of $72.2 million.

The company, however, reported a loss of 5 cents per share during the quarter, as it incurred more expenses related to its label expansion applications, besides higher marketing costs. However, this was narrower than analysts’ expectation of a loss of 11 cents per share.

Image for representation (Photo by Drew Hays on Unsplash)

According to Symphony Health, new prescriptions of Vascepa rose by about 80% in the first quarter of 2019, compared to the same period of the prior year. However, its net selling price declined modestly as an increased portion of prescriptions were derived from patients with lower net paying Medicare insurance coverage.

Licensing revenues, from the commercialization of Vascepa outside the US, were $0.5 million in Q1, compared to $0.1 million in the year-over period.

Amarin tops the market in Q1 on Vascepa strength

READ: THE QUESTION EVERY POT INVESTOR ASKS HIMSELF – AURORA CANNABIS OR HEXO?

Amarin CEO John Thero said, “We remain very early in the process of introducing Vascepa to healthcare professionals and we remain limited in what we can say about Vascepa, particularly to consumers, until the label for Vascepa is expanded.”

Amarin shares have gained 46% since the beginning of this year, outperforming the industry, which has grown just over 2%. Three events had set the stage for the stock rally this year: Rumors that Novartis (NYSE: NVS) was interested in acquiring it; a better-than-expected revenue growth in Q4; and reports that the American Diabetes Association had given a positive note on its Vascepa capsule.

Amarin’s Vascepa capsules lower fat level in blood by reducing triglycerides in the body when taken along with a proper diet.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

ISRG Earnings: Intuitive Surgical Q2 profit jumps on strong revenue growth

Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) announced operating results for the second quarter of 2024, reporting higher revenues and adjusted profit. Second-quarter net profit, excluding one-off items, climbed

Infographic: Halliburton (HAL) reports strong earnings growth for Q2 2024

Energy giant Halliburton Company (NYSE: HAL) Friday announced financial results for the second quarter of 2024, reporting a double-digit increase in net profit. Second-quarter revenue edged up 1% annually to

AXP Earnings: Key quarterly highlights from American Express’ Q2 2024 financial results

American Express Company (NYSE: AXP) reported its second quarter 2024 earnings results today. Consolidated total revenues, net of interest expense, were $16.3 billion, up 8% from a year ago, driven

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top